3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
42
Lung Neoplasms
13
Neoplasms
7
Brain Neoplasms
6
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
NSCLC
3
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Central Nervous System Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma, Bronchiolo-Alveolar
2
Adenocarcinoma of Lung
2
Tongue Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Diseases
1
Relapsed Pediatric Solid Tumor
1
Recurrence
1
Precancerous Conditions
1
Optic Nerve Glioma
1
Non-squamous Non-small Cell Lung Cancer
1
Metastatic Pancreatic Adenocarcinoma
1
Medulloblastoma
1
Lung Diseases
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Familial ependymoma
1
Interventions
Pemetrexed
4
anlotinib
3
Platinum
2
Bevacizumab
2
icotinib
1
endostar protein
1
Gefitinib
1
Erlotinib Hydrochloride
1
Docetaxel
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Non-squamous Non-small Cell Lung Cancer
×
Erlotinib Hydrochloride
×
Clear all
NCT02633189
2023-03-24
BEVERLY
National Cancer Institute, Naples
Phase 3
Unknown
200 enrolled